Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Hønefoss – page 15

606 clinical trials in Hønefoss, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Hønefoss at a glance
606
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

606 trials in Hønefoss

Open in trial search

Uveal melanoma

Recruiting

Title: Comparing tebentafusp treatment versus observation in patients with high-risk eye melanoma (uveal melanoma) after initial treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tebentafusp
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Cataract

Recruiting

Study on Reducing Inflammation After Cataract Surgery Using Nepafenac and Dexamethasone for Patients Undergoing Surgery

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Oslo University Hospital HF

Study on Bortezomib and Temozolomide for Patients with Recurrent Grade IV Glioma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Helse Bergen HF

Diabetes mellitus+1

Recruiting

Study on the Safety and Effectiveness of VX-880 for Patients with Type 1 Diabetes and Severe Low Blood Sugar Awareness

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zimislecel
  • Sponsor:Vertex Pharmaceuticals Inc.

Study of Avapritinib for Adults with Systemic Mastocytosis Who Previously Participated in an Avapritinib Study

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Study on the Effects of Dendritic Cell Immunotherapy and Temozolomide in Patients with Glioblastoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Oslo University Hospital HF

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Ruxolitinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study of Elenestinib for Patients with Indolent Systemic Mastocytosis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Elenestinib Phosphate
  • Sponsor:Blueprint Medicines Corp.

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Study on Ifosfamide and Doxorubicin for Patients with High-Grade Soft Tissue Sarcoma in the Limbs and Trunk Wall

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ifosfamide
  • Sponsor:Oslo University Hospital HF

Study of ART27.13 for Patients with Cancer-Related Anorexia and Weight Loss

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:AZD1940
  • Sponsor:Artelo Biosciences Limited

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Hønefoss

What the registry says about research in the country

01 Musculoskeletal Diseases

In Hønefoss, researchers are evaluating non‑pharmacologic and medication approaches for acute neck pain. The study compares chiropractic spinal manipulative therapy with standard use of NSAIDs to determine which method best reduces pain intensity during the treatment period.

  • Comparative effectiveness of manual therapy versus medication
  • Measurement of pain intensity and functional recovery
  • Patient‑reported outcome measures
  • Safety and feasibility of combined treatment strategies

Findings aim to guide clinicians in selecting optimal first‑line interventions for neck pain, potentially improving recovery speed and patient satisfaction.

02 Bacterial Infections and Mycoses

Clinical investigators are studying patients with suspected community‑acquired sepsis to assess whether a regimen of narrow spectrum β‑lactam antibiotics together with an aminoglycoside is safe and non‑inferior to standard broad spectrum antibiotics. The goal is to refine early treatment choices while minimizing unnecessary broad‑spectrum exposure.

  • Early antibiotic stewardship in severe infections
  • Safety profiling of combination therapy
  • Efficacy comparison with broad‑spectrum regimens
  • Impact on patient outcomes and hospital stay

Results could support more targeted antibiotic use, preserving effectiveness of broad‑spectrum agents and reducing resistance development.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.